Vaccine supply chain: Resilience-by-design and resilience-by-intervention

[1]  Benjamin D. Trump,et al.  Supply chain resilience for vaccines: review of modeling approaches in the context of the COVID-19 pandemic , 2021, Ind. Manag. Data Syst..

[2]  Benjamin D. Trump,et al.  Enhancing Resilience in Post-COVID Societies: By Design or By Intervention? , 2021, Environmental science & technology.

[3]  R. Mullin.  Pfizer, Moderna ready vaccine manufacturing networks , 2020, C&EN Global Enterprise.

[4]  Benjamin D. Trump,et al.  The Vaccine Supply Chain: A Call for Resilience Analytics to Support COVID-19 Vaccine Production and Distribution , 2020, COVID-19: Systemic Risk and Resilience.

[5]  M. Slaoui,et al.  Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach. , 2020, The New England journal of medicine.

[6]  Igor Linkov,et al.  The case for value chain resilience , 2020 .

[7]  S. Routroy,et al.  A systematic literature review of healthcare supply chain and implications of future research , 2019, International Journal of Pharmaceutical and Healthcare Marketing.

[8]  Disaster Resilience.  DISASTER RESILIENCE: , 2019, Futureproof.

[9]  R. Pazdur,et al.  Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA). , 2019, Journal of Clinical Oncology.

[10]  Igor Linkov,et al.  Tiered Approach to Resilience Assessment , 2018, Risk analysis : an official publication of the Society for Risk Analysis.

[11]  S. Plotkin,et al.  The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.

[12]  M. Zoback,et al.  Disaster resilience: A national imperative , 2013 .

[13]  Emily P. Wen,et al.  Vaccine development and manufacturing , 2015 .